LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Case report: Ensitrelvir for treatment of persistent COVID-19 in lymphoma patients: a report of two cases.

    Furuya, Chiho / Yasuda, Hajime / Hiki, Makoto / Shirane, Shuichi / Yamana, Tomohito / Uchimura, Ayana / Inano, Tadaaki / Takaku, Tomoiku / Hamano, Yasuharu / Ando, Miki

    Frontiers in immunology

    2024  Volume 15, Page(s) 1287300

    Abstract: Persistent COVID-19 is a well recognized issue of concern in patients with hematological malignancies. Such patients are not only at risk of mortality due to the infection itself, but are also at risk of suboptimal malignancy-related outcomes because of ... ...

    Abstract Persistent COVID-19 is a well recognized issue of concern in patients with hematological malignancies. Such patients are not only at risk of mortality due to the infection itself, but are also at risk of suboptimal malignancy-related outcomes because of delays and terminations of chemotherapy. We report two lymphoma patients with heavily pretreated persistent COVID-19 in which ensitrelvir brought about radical changes in the clinical course leading to rapid remissions. Patient 1 was on ibrutinib treatment for mantle cell lymphoma when he developed COVID-19 pneumonia which was severe and ongoing for 2 months despite therapy with molnupiravir, multiple courses of remdesivir, one course of sotrovimab, tocilizumab, and steroids. Patient 2 was administered R-CHOP therapy for diffuse large B-cell lymphoma when he developed COVID-19 which was ongoing for a month despite treatment with multiple courses of remdesivir and one course of sotrovimab. A 5-day administration of ensitrelvir promptly resolved the persistent COVID-19 accommodated by negative conversions of RT-qPCR tests in both patients within days. Ensitrelvir is a novel COVID-19 therapeutic that accelerates viral clearance through inhibition of the main protease of SARS-CoV-2, 3-chymotrypsin-like protease, which is vital for viral replication. Ensitrelvir is a promising treatment approach for immunocompromised lymphoma patients suffering from persisting and severe COVID-19.
    MeSH term(s) Male ; Humans ; Adult ; COVID-19/complications ; SARS-CoV-2 ; Hematologic Neoplasms ; Lymphoma, Large B-Cell, Diffuse ; Indazoles ; Triazines ; Triazoles
    Chemical Substances ensitrelvir (PX665RAA3H) ; Indazoles ; Triazines ; Triazoles
    Language English
    Publishing date 2024-01-25
    Publishing country Switzerland
    Document type Case Reports ; Journal Article
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2024.1287300
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Successful management of acute graft-versus-host disease with ibrutinib during cord blood transplantation for germline

    Uchimura, Ayana / Yasuda, Hajime / Onagi, Hiroko / Inano, Tadaaki / Shirane, Shuichi / Ishii, Midori / Azusawa, Yoko / Hamano, Yasuharu / Eguchi, Hidetaka / Arai, Masami / Ando, Jun / Ando, Miki

    Heliyon

    2024  Volume 10, Issue 2, Page(s) e24801

    Abstract: Background: Acute graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with significant morbidity and mortality, and efficacy of currently available therapeutics are limited. Acute ... ...

    Abstract Background: Acute graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with significant morbidity and mortality, and efficacy of currently available therapeutics are limited. Acute and chronic GVHD are similar in that both are initiated by antigen presenting cells and activation of alloreactive B-cells and T-cells, subsequently leading to inflammation, tissue damage, and organ failure. One difference is that acute GVHD is mostly attributed to T-cell activation and cytokine release, whereas B-cells are the key players in chronic GVHD. Ibrutinib is an irreversible inhibitor of the Bruton's tyrosine kinase (BTK), which is part of B-cell receptor signaling. Ibrutinib is currently used for treating chronic GVHD, but its efficacy towards acute GVHD is unknown. Besides BTK, ibrutinib also inhibits interleukin-2 inducible T-cell kinase (ITK), which is predominantly expressed in T-cells and a crucial enzyme for activating the downstream pathway of TCR signaling. ITK activates PLCγ2 and facilitates signaling through NF-κB, NFAT, and MAPK, leading to activation and proliferation of T-cells and enhanced cytokine production. Therefore, the TCR signaling pathway is indispensable for development of acute GVHD, and ITK inhibition by ibrutinib would be a rational therapeutic approach.
    Case presentation: A 56-year-old male acute myeloid leukemia patient with Myeloid neoplasms with germline DEAD-box RNA helicase 41 (
    Conclusion: Ibrutinib is a promising therapeutic for treating acute GVHD, and further studies are warranted.
    Language English
    Publishing date 2024-01-17
    Publishing country England
    Document type Case Reports
    ZDB-ID 2835763-2
    ISSN 2405-8440
    ISSN 2405-8440
    DOI 10.1016/j.heliyon.2024.e24801
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin.

    Uchimura, Ayana / Yasuda, Hajime / Ando, Jun / Ota, Yasunori / Sasaki, Makoto / Takaku, Tomoiku / Tsukune, Yutaka / Tsutsui, Miyuki / Edahiro, Yoko / Watanabe, Naoki / Ochiai, Tomonori / Komatsu, Norio / Ando, Miki

    Case reports in oncology

    2022  Volume 15, Issue 1, Page(s) 263–266

    Abstract: Chemotherapy for hemodialysis (HD) patients is a challenging situation because HD patients are generally frail, and the pharmacokinetics and pharmacodynamics of most chemotherapeutics in HD patients are unknown. We report a classical Hodgkin lymphoma ( ... ...

    Abstract Chemotherapy for hemodialysis (HD) patients is a challenging situation because HD patients are generally frail, and the pharmacokinetics and pharmacodynamics of most chemotherapeutics in HD patients are unknown. We report a classical Hodgkin lymphoma (cHL) patient successfully treated with 34 courses of brentuximab vedotin (BV) monotherapy, of which 30 courses were carried out during HD. Although grade 2 peripheral sensory neuropathy and one occasion of febrile neutropenia were observed, treatment was well-tolerated overall and effective. This is the first report of successful BV administration in a cHL patient on HD, and also the first to report efficacy and safety of extended courses of BV in an HD patient. Treatment options for cHL in the HD patient are limited, and extended courses of BV monotherapy may be an optimal treatment approach for some patients.
    Language English
    Publishing date 2022-03-15
    Publishing country Switzerland
    Document type Case Reports
    ZDB-ID 2458961-5
    ISSN 1662-6575
    ISSN 1662-6575
    DOI 10.1159/000523823
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma.

    Yasuda, Hajime / Tsukune, Yutaka / Watanabe, Naoki / Sugimoto, Kazuya / Uchimura, Ayana / Tateyama, Misa / Miyashita, Yosuke / Ochi, Yusuke / Komatsu, Norio

    Clinical lymphoma, myeloma & leukemia

    2020  Volume 20, Issue 11, Page(s) 774–776

    MeSH term(s) Antibodies, Neutralizing/blood ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/blood ; Antibodies, Viral/immunology ; Antineoplastic Agents, Immunological/adverse effects ; Betacoronavirus/immunology ; Betacoronavirus/isolation & purification ; COVID-19 ; Chronic Disease ; Coronavirus Infections/blood ; Coronavirus Infections/complications ; Coronavirus Infections/diagnosis ; Coronavirus Infections/immunology ; Female ; Humans ; Lung/diagnostic imaging ; Lymphoma, Follicular/complications ; Lymphoma, Follicular/drug therapy ; Lymphoma, Follicular/immunology ; Middle Aged ; Pandemics ; Pneumonia, Viral/blood ; Pneumonia, Viral/complications ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/immunology ; Rituximab/adverse effects ; SARS-CoV-2 ; Tomography, X-Ray Computed
    Chemical Substances Antibodies, Neutralizing ; Antibodies, Viral ; Antineoplastic Agents, Immunological ; Rituximab (4F4X42SYQ6)
    Keywords covid19
    Language English
    Publishing date 2020-08-22
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2540992-X
    ISSN 2152-2669 ; 2152-2650
    ISSN (online) 2152-2669
    ISSN 2152-2650
    DOI 10.1016/j.clml.2020.08.017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5903: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma

    Yasuda, Hajime / Tsukune, Yutaka / Watanabe, Naoki / Sugimoto, Kazuya / Uchimura, Ayana / Tateyama, Misa / Miyashita, Yosuke / Ochi, Yusuke / Komatsu, Norio

    Clin Lymphoma Myeloma Leuk

    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #726475
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma

    Yasuda, Hajime / Tsukune, Yutaka / Watanabe, Naoki / Sugimoto, Kazuya / Uchimura, Ayana / Tateyama, Misa / Miyashita, Yosuke / Ochi, Yusuke / Komatsu, Norio

    Clinical Lymphoma Myeloma and Leukemia

    2020  Volume 20, Issue 11, Page(s) 774–776

    Keywords covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 2540992-X
    ISSN 2152-2669 ; 2152-2650
    ISSN (online) 2152-2669
    ISSN 2152-2650
    DOI 10.1016/j.clml.2020.08.017
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5903: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top